Preliminary Malaria Vaccine Trial a Success

An intravenous vaccine appears to protect adults from malaria infection in a Phase 1 clinical trial.

By | August 9, 2013

STEPHEN HOFFMAN, SANARIA INCA vaccine made from weakened malaria parasites appeared to protect participants in a small clinical trial from malaria infection, according to a study published yesterday (August 8) in Science.

“Scientists and health care providers have made significant gains in characterizing, treating, and preventing malaria,” said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), in a press release. “We are encouraged by this important step forward.”

Rockville, Maryland-based biotech Sanaria made the vaccine by irradiating parasite-infected mosquitoes, harvesting weakened parasites from the mosquitoes’ salivary glands, and cryopreserving them.

Researchers tested the vaccine by enrolling 57 adults in a trial carried out at the NIH Clinical Center in Bethesda, Maryland. They gave 40 subjects the vaccine in various doses, while the remaining 17 participants were controls.

None of the study participants had adverse reactions to the vaccine, and those who received higher doses were more likely to mount an antibody and T cell response to the parasite.

The participants were then exposed to malaria-carrying mosquitoes. Of the 15 people who were given a higher dose of the vaccine, only three were infected, while 16 of 17 of low-dose participants and 11 out of 12 controls were infected. (The people who were infected were treated with anti-malarial medication.)

Researchers have suspected that vaccinating subjects with irradiated whole parasites might be effective since the 1970s, when it was shown that bites from irradiated, malaria-infected mosquitoes appeared to protect people from the disease. But it has been difficult to isolate large quantities of whole, irradiated parasites.

One drawback of the vaccine is that it is delivered intravenously. Previous studies showed that simply injecting the vaccine into the skin or into the tissue beneath the skin was considerably less effective.

Nevertheless, Sanaria’s results excited the malaria research community. “The trial results constitute the most important advance in malaria vaccine development since the first demonstration of protection with radiation attenuated sporozoite immunization by mosquito bite in the ’70s,” Stefan Kappe, who studies malaria at the Seattle Biomedical Research Institute, told Nature.

The next step will be carrying out a trial in Tanzania to test whether the vaccine works against the diverse malaria strains present in Africa, Nature said.

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Man Receives First In Vivo Gene-Editing Therapy
  2. Researchers Build a Cancer Immunotherapy Without Immune Cells
  3. Immune Checkpoint Found Lacking in Type 1 Diabetes
  4. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.